Snehal Patel Acquires 1,800 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel acquired 1,800 shares of Greenwich LifeSciences stock in a transaction that occurred on Tuesday, January 7th. The stock was acquired at an average cost of $13.75 per share, with a total value of $24,750.00. Following the completion of the purchase, the chief executive officer now owns 5,550,002 shares in the company, valued at approximately $76,312,527.50. This represents a 0.03 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Snehal Patel also recently made the following trade(s):

• On Thursday, January 2nd, Snehal Patel bought 2,000 shares of Greenwich LifeSciences stock. The stock was acquired at an average price of $11.97 per share, for a total transaction of $23,940.00.
• On Monday, December 30th, Snehal Patel purchased 3,200 shares of Greenwich LifeSciences stock. The shares were bought at an average price of $11.12 per share, with a total value of $35,584.00.

Greenwich LifeSciences Stock Performance

Greenwich LifeSciences stock opened at $12.38 on Friday. Greenwich LifeSciences, Inc. has a twelve month low of $8.00 and a twelve month high of $21.44. The firm has a market cap of $162.74 million, a PE ratio of -15.47 and a beta of 1.66. The firm’s 50 day moving average price is $13.13 and its two-hundred day moving average price is $14.10.

Hedge Funds Weigh In On Greenwich LifeSciences

Hedge funds have recently modified their holdings of the stock. Rhumbline Advisers purchased a new position in Greenwich LifeSciences in the second quarter valued at about $117,000. Barclays PLC lifted its holdings in shares of Greenwich LifeSciences by 323.3% during the 3rd quarter. Barclays PLC now owns 8,560 shares of the company’s stock valued at $123,000 after buying an additional 6,538 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Greenwich LifeSciences in the 2nd quarter valued at approximately $264,000. Garden State Investment Advisory Services LLC acquired a new position in Greenwich LifeSciences in the third quarter worth approximately $253,000. Finally, State Street Corp raised its position in Greenwich LifeSciences by 4.4% during the third quarter. State Street Corp now owns 71,408 shares of the company’s stock valued at $1,026,000 after acquiring an additional 3,005 shares in the last quarter. 4.16% of the stock is owned by institutional investors and hedge funds.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.